Filing Details
- Accession Number:
- 0001209191-23-016074
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-03 20:37:20
- Reporting Period:
- 2023-03-01
- Accepted Time:
- 2023-03-03 20:37:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1557746 | Aclaris Therapeutics Inc. | ACRS | Pharmaceutical Preparations (2834) | 460571712 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1604457 | Neal Walker | C/O Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne PA 19087 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-03-01 | 96,150 | $0.00 | 1,271,913 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-03-01 | 18,275 | $0.00 | 1,290,188 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-03-01 | 24,000 | $0.00 | 1,314,188 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-03-02 | 29,000 | $12.37 | 1,285,188 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-03-02 | 18,254 | $0.00 | 1,303,442 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-03-03 | 30,240 | $12.63 | 1,273,202 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2023-03-01 | 96,150 | $0.00 | 96,150 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2023-03-01 | 18,275 | $0.00 | 18,275 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2023-03-01 | 24,000 | $0.00 | 24,000 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2023-03-02 | 18,254 | $0.00 | 18,254 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | M | Direct | ||
| 36,550 | No | 4 | M | Direct | ||
| 72,000 | No | 4 | M | Direct | ||
| 18,254 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 pursuant to preexisting sell-to-cover elections.
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.88 to $12.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 and March 2, 2023 pursuant to preexisting sell-to-cover elections.
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.39 to $12.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.
- The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.
- The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.
- The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.
Billionaire Hedge Funds
